{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:37:15Z","timestamp":1791412635039,"version":"4.3.3"},"reference-count":47,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,12,11]]},"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thromboembolism (TE) in cancer significantly contributes to morbidity and mortality. Little is known about the incidence of arterial TE (ATE) and venous TE (VTE) in patients with melanoma on immune checkpoint inhibitor (ICI) therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of patients with melanoma receiving ICI from July 2015 through December 2017 at the Cleveland Clinic. TE, including VTE events of deep venous thrombosis, pulmonary embolism, visceral vein thrombosis, and ATE events of myocardial infarction, stroke, peripheral arterial embolism, or transient ischemic attack after ICI initiation were identified. Overall survival (OS) from ICI initiation was estimated by Kaplan-Meier and Cox hazard models; associations between TE, ICI regimen, and clinical risk factors were evaluated using log-rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study population comprised 228 patients with median age of 65 years (23\u201391 years), 67% male, and median follow-up of 27.3 months. Pembrolizumab was most commonly used (38.7%), followed by combination of ipilimumab plus nivolumab (29.4%), ipilimumab (20%), and nivolumab (12.3%). Most had stage IV disease (81.1%) and 11% had brain metastases (BM) at treatment initiation. Fifty-one TE events occurred in 47 patients (20.6%), including 37 (16.2%) VTE and 14 (6.1%) ATE. Cumulative incidence of TE after ICI initiation was 9.3% (95% CI: 6.0% to 13.6%) at 6 months, and 16.0% (95% CI: 11.6% to 21.2%) at 12 months. The 6-month and 12-month VTE cumulative incidence rates were higher with combination ICI than single agent (16.7% vs 5.0% and 21.3% vs 9.5%, respectively; p=0.02). Risk factors significantly associated with VTE in multivariate analysis included combination ICI (HR 2.70; 95%\u2009CI: 1.28 to 5.70; p=0.009), Khorana Score \u22651 (HR 2.24; 95%\u2009CI: 1.06 to 4.74; p=0.03), history of coronary artery disease (HR 2.71; 95%\u2009CI: 1.16 to 6.29); p=0.02), and anticoagulation at treatment start (HR 4.14; 95% CI: 1.60 to 10.7; p=0.003). Of patients without BM, OS was worse in patients with TE compared with those without (2-year OS 50.8% vs 71.3%; HR 2.27; 95%\u2009CI: 1.36 to 3.79; p=0.002), when adjusted for age and stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ICI is associated with a high incidence of TE in patients with melanoma, with higher rates with combination therapy; TE is associated with substantial worsening of survival. Further studies are needed to identify pathophysiology, biomarkers, and preventive approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2020-001719","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T20:00:25Z","timestamp":1610481625000},"page":"e001719","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":108,"title":["Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3429-4468","authenticated-orcid":false,"given":"Tamara A","family":"Sussman","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Department of Population Health, Dell Medical School, The University of Texas at Austin, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Funchain","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R","family":"McCrae","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok A","family":"Khorana","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"2025100311493871000_9.1.e001719.1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23062"},{"key":"2025100311493871000_9.1.e001719.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.6.715"},{"key":"2025100311493871000_9.1.e001719.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012213432504"},{"key":"2025100311493871000_9.1.e001719.4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0226"},{"key":"2025100311493871000_9.1.e001719.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02374.x"},{"key":"2025100311493871000_9.1.e001719.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.06.047"},{"key":"2025100311493871000_9.1.e001719.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116327"},{"key":"2025100311493871000_9.1.e001719.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270116"},{"key":"2025100311493871000_9.1.e001719.9","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-04-0241"},{"key":"2025100311493871000_9.1.e001719.10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jth.14630","article-title":"Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors","volume":"18","author":"Gervaso","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2025100311493871000_9.1.e001719.11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr592"},{"key":"2025100311493871000_9.1.e001719.12","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-13-1138"},{"key":"2025100311493871000_9.1.e001719.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03795.x"},{"key":"2025100311493871000_9.1.e001719.14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s10637-019-00881-6","article-title":"Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors","volume":"38","author":"Ando","year":"2020","journal-title":"Invest New Drugs"},{"key":"2025100311493871000_9.1.e001719.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"2025100311493871000_9.1.e001719.16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.thromres.2017.01.009","article-title":"Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial","volume":"151","author":"Khorana","year":"2017","journal-title":"Thromb Res"},{"key":"2025100311493871000_9.1.e001719.17","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2013.0163"},{"key":"2025100311493871000_9.1.e001719.18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100311493871000_9.1.e001719.19","doi-asserted-by":"publisher","DOI":"10.2307\/2670170"},{"key":"2025100311493871000_9.1.e001719.20","doi-asserted-by":"publisher","DOI":"10.1109\/TAC.1974.1100705"},{"key":"2025100311493871000_9.1.e001719.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.04.030"},{"key":"2025100311493871000_9.1.e001719.22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2019.06.021","article-title":"Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study","volume":"120","author":"Bar","year":"2019","journal-title":"Eur J Cancer"},{"key":"2025100311493871000_9.1.e001719.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9"},{"key":"2025100311493871000_9.1.e001719.24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2340\/00015555-2504","article-title":"Acute lower limb ischaemia and diabetes in a patient treated with anti-PD1 monoclonal antibody for metastatic melanoma","volume":"97","author":"Thoreau","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2025100311493871000_9.1.e001719.25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejca.2017.11.018","article-title":"Arterial thrombosis and anti-PD-1 blockade","volume":"91","author":"Boutros","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025100311493871000_9.1.e001719.26","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis","volume":"6","author":"Hu","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"2025100311493871000_9.1.e001719.27","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.2018.36.15_suppl.3009","article-title":"Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: a U.S. food and drug administration pooled analysis","volume":"36","author":"Amiri-Kordestani","year":"2018","journal-title":"JCO"},{"key":"2025100311493871000_9.1.e001719.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2351"},{"key":"2025100311493871000_9.1.e001719.29","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1002\/1097-0142(19920615)69:12<2884::AID-CNCR2820691204>3.0.CO;2-S","article-title":"Peaks in plasma plasminogen activator inhibitor-1 concentration may explain thrombotic events in cases of pancreatic carcinoma","volume":"69","author":"Andr\u00e9n-Sandberg","year":"1992","journal-title":"Cancer"},{"key":"2025100311493871000_9.1.e001719.30","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.24068"},{"key":"2025100311493871000_9.1.e001719.31","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10783"},{"key":"2025100311493871000_9.1.e001719.32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.12.4533"},{"key":"2025100311493871000_9.1.e001719.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2008.12.009"},{"key":"2025100311493871000_9.1.e001719.34","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/jcm8060762","article-title":"Disorder of coagulation-fibrinolysis system: an emerging toxicity of anti-PD-1\/PD-L1 monoclonal antibodies","volume":"8","author":"Sato","year":"2019","journal-title":"J Clin Med"},{"key":"2025100311493871000_9.1.e001719.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2016.10.010"},{"key":"2025100311493871000_9.1.e001719.36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093280"},{"key":"2025100311493871000_9.1.e001719.37","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.111.224709"},{"key":"2025100311493871000_9.1.e001719.38","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41591-020-0964-7","article-title":"Myocardial infarction accelerates breast cancer via innate immune reprogramming","volume":"26","author":"Koelwyn","year":"2020","journal-title":"Nat Med"},{"key":"2025100311493871000_9.1.e001719.39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3206"},{"key":"2025100311493871000_9.1.e001719.40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.24.11832"},{"key":"2025100311493871000_9.1.e001719.41","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.21.1580"},{"key":"2025100311493871000_9.1.e001719.42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1142"},{"key":"2025100311493871000_9.1.e001719.43","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dys146"},{"key":"2025100311493871000_9.1.e001719.44","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-011-9766-z"},{"key":"2025100311493871000_9.1.e001719.45","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"2025100311493871000_9.1.e001719.46","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"2025100311493871000_9.1.e001719.47","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e328353efd8"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:49:51Z","timestamp":1759517391000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,12]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1136\/jitc-2020-001719"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001719","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}